Annovis Bio, Inc. (NYSE: ANVS)
$6.7650
-0.0250 ( -1.24% ) 84.0K
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Market Data
Open
$6.7650
Previous close
$6.7900
Volume
84.0K
Market cap
$93.68M
Day range
$6.7500 - $7.0200
52 week range
$4.5300 - $22.4900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 10-q | Quarterly Reports | 60 | May 10, 2024 |
| 8-k | 8K-related | 14 | May 09, 2024 |
| 8-k | 8K-related | 14 | May 06, 2024 |
| 8-k | 8K-related | 15 | May 02, 2024 |
| 8-k | 8K-related | 14 | May 01, 2024 |
| ars | Annual reports | 1 | Apr 29, 2024 |
| def | Proxies and info statements | 4 | Apr 29, 2024 |
| 8-k | 8K-related | 15 | Apr 26, 2024 |
| 8-k | 8K-related | 15 | Apr 03, 2024 |
| 10-k | Annual reports | 85 | Mar 29, 2024 |